JP6255382B2 - ヒトヒストンメチルトランスフェラーゼｅｚｈ２阻害剤の塩形態 - Google Patents

ヒトヒストンメチルトランスフェラーゼｅｚｈ２阻害剤の塩形態 Download PDF

Info

Publication number
JP6255382B2
JP6255382B2 JP2015505912A JP2015505912A JP6255382B2 JP 6255382 B2 JP6255382 B2 JP 6255382B2 JP 2015505912 A JP2015505912 A JP 2015505912A JP 2015505912 A JP2015505912 A JP 2015505912A JP 6255382 B2 JP6255382 B2 JP 6255382B2
Authority
JP
Japan
Prior art keywords
cancer
polymorph
compound
methyl
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015505912A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015512942A (ja
JP2015512942A5 (enExample
Inventor
クーンツ，ケビン・ウェイン
ホワン，クワン−チュン
チョイ，ヒョン・ウク
サンダース，クリステン
マチュー，スティーブン
チャンダ，アラニ
ファン，フランク
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai R&D Management Co Ltd
Original Assignee
Eisai R&D Management Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Management Co Ltd filed Critical Eisai R&D Management Co Ltd
Publication of JP2015512942A publication Critical patent/JP2015512942A/ja
Publication of JP2015512942A5 publication Critical patent/JP2015512942A5/ja
Application granted granted Critical
Publication of JP6255382B2 publication Critical patent/JP6255382B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
JP2015505912A 2012-04-13 2013-04-11 ヒトヒストンメチルトランスフェラーゼｅｚｈ２阻害剤の塩形態 Active JP6255382B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261624215P 2012-04-13 2012-04-13
US61/624,215 2012-04-13
PCT/US2013/036193 WO2013155317A1 (en) 2012-04-13 2013-04-11 Salt form of a human hi stone methyltransf erase ezh2 inhibitor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017198642A Division JP6634058B2 (ja) 2012-04-13 2017-10-12 ヒトヒストンメチルトランスフェラーゼｅｚｈ２阻害剤の塩形態

Publications (3)

Publication Number Publication Date
JP2015512942A JP2015512942A (ja) 2015-04-30
JP2015512942A5 JP2015512942A5 (enExample) 2016-06-09
JP6255382B2 true JP6255382B2 (ja) 2017-12-27

Family

ID=49328166

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2015505912A Active JP6255382B2 (ja) 2012-04-13 2013-04-11 ヒトヒストンメチルトランスフェラーゼｅｚｈ２阻害剤の塩形態
JP2017198642A Active JP6634058B2 (ja) 2012-04-13 2017-10-12 ヒトヒストンメチルトランスフェラーゼｅｚｈ２阻害剤の塩形態
JP2018187463A Pending JP2018199740A (ja) 2012-04-13 2018-10-02 ヒトヒストンメチルトランスフェラーゼｅｚｈ２阻害剤の塩形態

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2017198642A Active JP6634058B2 (ja) 2012-04-13 2017-10-12 ヒトヒストンメチルトランスフェラーゼｅｚｈ２阻害剤の塩形態
JP2018187463A Pending JP2018199740A (ja) 2012-04-13 2018-10-02 ヒトヒストンメチルトランスフェラーゼｅｚｈ２阻害剤の塩形態

Country Status (26)

Country Link
US (7) US9394283B2 (enExample)
EP (4) EP3628670B1 (enExample)
JP (3) JP6255382B2 (enExample)
KR (4) KR20250005505A (enExample)
CN (2) CN104603130B (enExample)
AU (2) AU2013245878B2 (enExample)
BR (1) BR112014025508B1 (enExample)
CA (1) CA2870005C (enExample)
CY (2) CY1119383T1 (enExample)
DK (3) DK3184523T3 (enExample)
ES (3) ES2617379T3 (enExample)
HR (2) HRP20170295T1 (enExample)
HU (3) HUE031976T2 (enExample)
IL (4) IL282732B2 (enExample)
IN (1) IN2014DN09068A (enExample)
LT (2) LT2836491T (enExample)
MX (2) MX384641B (enExample)
NZ (1) NZ700761A (enExample)
PL (3) PL2836491T3 (enExample)
PT (3) PT3628670T (enExample)
RS (2) RS55690B1 (enExample)
RU (1) RU2658911C2 (enExample)
SG (3) SG10201912109QA (enExample)
SI (2) SI2836491T1 (enExample)
SM (2) SMT201900501T1 (enExample)
WO (1) WO2013155317A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018002742A (ja) * 2012-04-13 2018-01-11 エピザイム，インコーポレイティド ヒトヒストンメチルトランスフェラーゼｅｚｈ２阻害剤の塩形態

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3363B1 (ar) 2011-04-13 2019-03-13 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
WO2013075084A1 (en) 2011-11-18 2013-05-23 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
US9085583B2 (en) 2012-02-10 2015-07-21 Constellation—Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
EP2836216B1 (en) 2012-04-13 2022-06-08 Epizyme, Inc. Combination therapy for treating cancer
US9562041B2 (en) 2012-05-16 2017-02-07 Glaxosmithkline Llc Enhancer of zeste homolog 2 inhibitors
KR20190105669A (ko) 2012-10-15 2019-09-17 에피자임, 인코포레이티드 암을 치료하는 방법
BR112015008480A2 (pt) * 2012-10-15 2017-07-04 Epizyme Inc compostos de benzeno substituído
US9745305B2 (en) 2013-03-15 2017-08-29 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
HK1214815A1 (zh) 2013-04-30 2016-08-05 Glaxosmithkline Intellectual Property (No. 2) Limited Zeste增强子同源物2的抑制剂
CA2917463A1 (en) 2013-07-10 2015-01-15 Glaxosmithkline Intellectual Property (No.2) Limited Enhancer of zeste homolog 2 inhibitors
US9969716B2 (en) 2013-08-15 2018-05-15 Constellation Pharmaceuticals, Inc. Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof
PE20161273A1 (es) 2013-10-16 2016-12-18 Epizyme Inc Forma salina de hidrocloruro para la inhibicion de ezh2
WO2015058125A1 (en) * 2013-10-18 2015-04-23 Epizyme, Inc. Method of treating cancer
US9738630B2 (en) 2013-11-19 2017-08-22 Bristol-Myers Squibb Company Inhibitors of lysine methyl transferase
MX373187B (es) 2013-12-06 2020-04-13 Epizyme Inc Terapia de combinación para tratar cáncer.
EA038337B1 (ru) 2014-06-17 2021-08-11 Эпизим, Инк. Ингибиторы ezh2 для лечения лимфомы
CN106687463B (zh) 2014-06-20 2019-04-09 星座制药公司 一种乙酰胺类化合物的晶型
CN106794177A (zh) 2014-10-16 2017-05-31 Epizyme股份有限公司 治疗癌症的方法
KR102964530B1 (ko) 2014-11-17 2026-05-13 에피자임, 인코포레이티드 암을 치료하기 위한 방법
TW201636344A (zh) 2014-12-05 2016-10-16 美國禮來大藥廠 Ｅｚｈ２抑制劑
MX391720B (es) 2015-04-20 2025-03-21 Epizyme Inc Terapia combinada para tratar cáncer.
EA201890009A1 (ru) 2015-06-10 2018-07-31 Эпизайм, Инк. Ингибиторы ezh2 для лечения лимфомы
WO2017035234A1 (en) 2015-08-24 2017-03-02 Epizyme, Inc. Method for treating cancer
TW201718598A (zh) 2015-08-27 2017-06-01 美國禮來大藥廠 Ｅｚｈ２抑制劑
WO2017040190A1 (en) 2015-08-28 2017-03-09 Constellation Pharmaceuticals, Inc. Crystalline forms of (r)-n-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1h-indole-3-carboxamide
US11951108B2 (en) 2016-01-29 2024-04-09 Epizyme, Inc. Combination therapy for treating cancer
US11786533B2 (en) 2016-06-01 2023-10-17 Epizyme, Inc. Use of EZH2 inhibitors for treating cancer
US11147819B2 (en) 2016-06-17 2021-10-19 Epizyme, Inc. EZH2 inhibitors for treating cancer
WO2018075598A1 (en) 2016-10-19 2018-04-26 Constellation Pharmaceuticals, Inc. Synthesis of inhibitors of ezh2
CN110191879A (zh) * 2017-01-25 2019-08-30 恩瑞生物医药科技（上海）有限公司 一种组蛋白甲基转移酶ezh2抑制剂、其制备方法及其医药用途
WO2018183885A1 (en) 2017-03-31 2018-10-04 Epizyme, Inc. Combination therapy for treating cancer
AU2018275123A1 (en) 2017-06-02 2020-01-30 Epizyme, Inc. Use of EZH2 inhibitors for treating cancer
JP7399079B2 (ja) 2017-09-05 2023-12-15 エピザイム，インコーポレイティド 癌を処置するための併用療法
MX2020010999A (es) 2018-04-18 2021-01-20 Constellation Pharmaceuticals Inc Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos.
WO2020011607A1 (en) 2018-07-09 2020-01-16 Fondation Asile Des Aveugles Inhibition of prc2 subunits to treat eye disorders
PE20220562A1 (es) 2019-07-24 2022-04-13 Constellation Pharmaceuticals Inc Formas cristalinas de 7-cloro-2-(4-(3-metoxiazetidin-1-il)ciclohexil)-2,4-dimetil-n-((6-metil-4-(metiltio)-2-oxo-1,2-dihidropiridin-3-il)metil)benzo[d][1,3]dioxol-5-carboxamida
KR20220066892A (ko) 2019-08-22 2022-05-24 주노 쎄러퓨티크스 인코퍼레이티드 Ｔ 세포 요법 및 제스트 동족체 2의 인핸서 (ｅｚｈ2) 억제제의 병용 요법 및 관련 방법
KR20220130698A (ko) * 2019-12-20 2022-09-27 에피자임, 인코포레이티드 Ezh2 억제제의 결정질 하이드로브로마이드 염, 이의 제조 및 암의 치료에 유용한 약학적 조성물
WO2022208552A1 (en) * 2021-03-31 2022-10-06 Msn Laboratories Private Limited, R&D Center Crystalline forms of [1,1'-Biphenyl]-3-carboxamide, N-[(1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl]-5-[ethyl(tetrahydro-2H-pyran-4-yl)amino]-4-methyl-4'-(4-morpholinylmethyl)-, hydrobromide (1:1) and process for its preparation thereof
KR20260019479A (ko) 2023-05-04 2026-02-10 레볼루션 메디슨즈, 인크. Ras 관련 질환 또는 장애를 위한 병용 요법
CN121889155A (zh) 2023-08-07 2026-04-17 锐新医药公司 用于治疗ras蛋白相关疾病或病症的rmc-6291
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer
WO2026106912A1 (en) 2024-11-12 2026-05-21 Revolution Medicines, Inc. Ras inhibitors
WO2026112260A1 (en) 2024-11-21 2026-05-28 Revolution Medicines, Inc. Ras inhibitors
WO2026117542A1 (en) 2024-11-26 2026-06-04 Arvinas Operations, Inc. Combination therapy for the targeted degradation of bcl6
WO2026122764A2 (en) 2024-12-06 2026-06-11 Revolution Medicines, Inc. Ras inhibitors
WO2026128688A2 (en) 2024-12-13 2026-06-18 Revolution Medicines, Inc. Ras inhibitors
WO2026161839A1 (en) 2025-01-27 2026-07-30 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0733729A (ja) 1993-07-26 1995-02-03 Kirin Brewery Co Ltd Ｎ−シアノ−ｎ′−置換−アリールカルボキシイミダミド化合物の製造法
CA2155662A1 (en) 1993-12-27 1995-07-06 Fumihiro Ozaki Anthranilic acid derivative
DE19516776A1 (de) 1995-05-10 1996-11-14 Boehringer Ingelheim Int Chromatin-Regulatorgene
US5741819A (en) 1995-06-07 1998-04-21 3-Dimensional Pharmaceuticals, Inc. Arylsulfonylaminobenzene derivatives and the use thereof as factor Xa inhibitors
JP3906935B2 (ja) 1995-12-18 2007-04-18 杏林製薬株式会社 Ｎ−置換ジオキソチアゾリジルベンズアミド誘導体及びその製造法
CN1332722A (zh) 1998-09-30 2002-01-23 宝洁公司 2－取代的酮酰胺
UA71587C2 (uk) 1998-11-10 2004-12-15 Шерінг Акцієнгезелльшафт Аміди антранілової кислоти та їхнє застосування як лікарських засобів
US6710058B2 (en) 2000-11-06 2004-03-23 Bristol-Myers Squibb Pharma Company Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors
DE60139506D1 (de) 2000-12-28 2009-09-17 Shionogi & Co 2-pyridonderivate mit affinität für den cannabinoid-typ-2-rezeptor
US7700293B2 (en) 2001-08-02 2010-04-20 The Regents Of The University Of Michigan Expression profile of prostate cancer
TW200303304A (en) * 2002-02-18 2003-09-01 Astrazeneca Ab Chemical compounds
WO2003070277A1 (en) 2002-02-19 2003-08-28 Shionogi & Co., Ltd. Antipruritics
TW200306155A (en) 2002-03-19 2003-11-16 Du Pont Benzamides and advantageous compositions thereof for use as fungicides
US7442685B2 (en) 2003-06-13 2008-10-28 The University Of North Carolina At Chapel Hill DOT1 histone methyltransferases as a target for identifying therapeutic agents for leukemia
WO2005095386A1 (en) 2004-03-30 2005-10-13 Chiron Corporation Substituted thiophene derivatives as anti-cancer agents
JP5160885B2 (ja) 2004-06-01 2013-03-13 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル 再構成ヒストンメチルトランスフェラーゼ複合体及びそのモジュレーターの識別方法
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
US7923219B2 (en) 2005-06-02 2011-04-12 The University Of North Carolina At Chapel Hill Ubiquitin E3 ligase
FR2889526B1 (fr) 2005-08-04 2012-02-17 Aventis Pharma Sa 7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation
WO2007045462A2 (de) 2005-10-19 2007-04-26 Grünenthal GmbH Neue vanilloid-rezeptor liganden und ihre verwendung zur herstellung von arzneimitteln
RU2008119994A (ru) 2005-10-21 2009-12-10 Мерк энд Ко., Инк. (US) Ингибиторы калиевых каналов
JP5078901B2 (ja) 2005-10-28 2012-11-21 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル ＪｍｊＣドメインを含むタンパク質デメチラーゼ
AU2006325746A1 (en) 2005-12-14 2007-06-21 Bristol-Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
WO2007087015A1 (en) 2006-01-20 2007-08-02 The University Of North Carolina At Chapel Hill Diagnostic and therapeutic targets for leukemia
EP2018166A2 (en) 2006-05-15 2009-01-28 Irm Llc Terephthalamate compounds and compositions, and their use as hiv integrase inhibitors
EP2040711A2 (en) 2006-05-18 2009-04-01 Amphora Discovery Corporation 2-oxo-1,2-dihydroquinoline derivatives, compositions, and uses thereof as antiproliferative agents
WO2008108825A2 (en) 2006-10-10 2008-09-12 Burnham Institute For Medical Research Neuroprotective compositions and methods
CA2676173A1 (en) 2007-02-16 2008-08-28 Amgen Inc. Nitrogen-containing heterocyclyl ketones and their use as c-met inhibitors
US8338437B2 (en) 2007-02-28 2012-12-25 Methylgene Inc. Amines as small molecule inhibitors
WO2008113006A1 (en) 2007-03-14 2008-09-18 Xenon Pharmaceuticals Inc. Methods of using quinolinone compounds in treating sodium channel-mediated diseases or conditions
DE102007017884A1 (de) 2007-04-13 2008-10-16 Grünethal GmbH Neue Vanilloid-Rezeptor Liganden und ihre Verwendung zur Herstellung von Arzneimitteln
WO2009006577A2 (en) 2007-07-03 2009-01-08 The Regents Of The University Of Michigan Compositions and methods for inhibiting ezh2
DE102007047737A1 (de) * 2007-10-05 2009-04-30 Merck Patent Gmbh Piperidin- und Piperazinderivate
WO2009058298A1 (en) 2007-10-31 2009-05-07 Merck & Co., Inc. P2x3, receptor antagonists for treatment of pain
NZ586418A (en) 2007-12-19 2012-09-28 Cancer Rec Tech Ltd Pyrido[2,3-b]pyrazine-8-substituted compounds and their use
WO2009124137A2 (en) 2008-04-01 2009-10-08 Mount Sinai School Of Medicine Of New York University Method of suppressing gene transcription through histone lysine methylation
US20100113415A1 (en) 2008-05-29 2010-05-06 Rajapakse Hemaka A Epha4 rtk inhibitors for treatment of neurological and neurodegenerative disorders and cancer
AU2009279616A1 (en) 2008-08-08 2010-02-11 New York Blood Center Small molecule inhibitors of retroviral assembly and maturation
FR2934995B1 (fr) 2008-08-14 2010-08-27 Sanofi Aventis Composes d'azetidines polysubstitues, leur preparation et leur application en therapeutique
JP2012522013A (ja) 2009-03-27 2012-09-20 ザ ユーエービー リサーチ ファウンデーション 調節ｉｒｅｓ媒介翻訳
WO2011011366A2 (en) 2009-07-20 2011-01-27 Constellation Pharmaceuticals Agents for stimulating activity of methyl modifying enzymes and methods of use thereof
EP2521558A4 (en) 2009-12-30 2013-07-03 Avon Prod Inc TOPICAL LIGHTING COMPOSITION AND USES THEREOF
WO2012005805A1 (en) * 2010-05-07 2012-01-12 Glaxosmithkline Llc Azaindazoles
MX2012012966A (es) * 2010-05-07 2013-01-22 Glaxosmithkline Llc Indoles.
US8846935B2 (en) * 2010-05-07 2014-09-30 Glaxosmithkline Llc Indazoles
BR112013005806B1 (pt) 2010-09-10 2022-05-10 Epizyme, Inc Métodos para detectar se um indivíduo é um candidato para o tratamento com ou responsivo a um inibidor de ezh2 e usos terapêuticos do dito inibidor de ezh2
US9175331B2 (en) 2010-09-10 2015-11-03 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
WO2012068589A2 (en) 2010-11-19 2012-05-24 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
EP2646020B1 (en) 2010-12-01 2016-09-21 Glaxosmithkline LLC Indoles
EP2646454B1 (en) 2010-12-03 2015-07-08 Epizyme, Inc. 7-deazapurine modulators of histone methyltransferase, and methods of use thereof
WO2012118812A2 (en) 2011-02-28 2012-09-07 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
JO3363B1 (ar) 2011-04-13 2019-03-13 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
TW201733984A (zh) 2011-04-13 2017-10-01 雅酶股份有限公司 經取代之苯化合物
CA3177515A1 (en) 2012-03-12 2013-09-19 Epizyme, Inc. Inhibitors of human ezh2, and methods of use thereof
EP2836216B1 (en) 2012-04-13 2022-06-08 Epizyme, Inc. Combination therapy for treating cancer
ES2617379T3 (es) 2012-04-13 2017-06-16 Epizyme, Inc. Forma de sal de un inhibidor de histona metiltransferasa EZH2 humana
US9562041B2 (en) 2012-05-16 2017-02-07 Glaxosmithkline Llc Enhancer of zeste homolog 2 inhibitors
KR20190105669A (ko) 2012-10-15 2019-09-17 에피자임, 인코포레이티드 암을 치료하는 방법
PE20161273A1 (es) 2013-10-16 2016-12-18 Epizyme Inc Forma salina de hidrocloruro para la inhibicion de ezh2

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018002742A (ja) * 2012-04-13 2018-01-11 エピザイム，インコーポレイティド ヒトヒストンメチルトランスフェラーゼｅｚｈ２阻害剤の塩形態

Also Published As

Publication number Publication date
CN108358899B (zh) 2021-07-27
IN2014DN09068A (enExample) 2015-05-22
NZ700761A (en) 2016-09-30
MX384641B (es) 2025-03-14
SG11201406468YA (en) 2015-01-29
LT3184523T (lt) 2020-02-10
CN104603130A (zh) 2015-05-06
RU2658911C2 (ru) 2018-06-26
ES2931316T3 (es) 2022-12-28
DK3628670T3 (da) 2022-12-05
SI2836491T1 (sl) 2017-06-30
PT2836491T (pt) 2017-02-08
US9872862B2 (en) 2018-01-23
SMT201700132T1 (it) 2017-05-08
CY1122883T1 (el) 2022-03-24
KR20150002730A (ko) 2015-01-07
LT2836491T (lt) 2017-03-27
JP6634058B2 (ja) 2020-01-22
US20180243316A1 (en) 2018-08-30
CN104603130B (zh) 2018-04-27
IL282732B (en) 2022-12-01
PT3184523T (pt) 2019-09-26
SG10201912109QA (en) 2020-02-27
IL235045B (en) 2019-05-30
IL296199A (en) 2022-11-01
EP3184523A1 (en) 2017-06-28
EP2836491A4 (en) 2015-09-16
EP3628670A1 (en) 2020-04-01
IL282732B2 (en) 2023-04-01
CN108358899A (zh) 2018-08-03
IL235045A0 (en) 2014-12-31
CA2870005C (en) 2021-06-22
JP2018002742A (ja) 2018-01-11
US20250268905A1 (en) 2025-08-28
PL2836491T3 (pl) 2017-08-31
IL282732A (en) 2021-06-30
KR20220123339A (ko) 2022-09-06
US10245269B2 (en) 2019-04-02
US9394283B2 (en) 2016-07-19
RS59392B1 (sr) 2019-11-29
KR20200066380A (ko) 2020-06-09
EP2836491B1 (en) 2016-12-07
IL296199B1 (en) 2024-08-01
HRP20170295T1 (hr) 2017-04-21
WO2013155317A1 (en) 2013-10-17
US10821113B2 (en) 2020-11-03
BR112014025508B1 (pt) 2020-11-17
CA2870005A1 (en) 2013-10-17
SMT201900501T1 (it) 2019-11-13
US20150065503A1 (en) 2015-03-05
EP4190777A1 (en) 2023-06-07
JP2015512942A (ja) 2015-04-30
SG10201608577RA (en) 2016-12-29
CY1119383T1 (el) 2018-02-14
IL266165B (en) 2021-06-30
HUE060881T2 (hu) 2023-04-28
PT3628670T (pt) 2022-12-02
US20190269692A1 (en) 2019-09-05
EP3184523B1 (en) 2019-06-19
HUE031976T2 (en) 2017-08-28
KR102744039B1 (ko) 2024-12-17
US20230140327A1 (en) 2023-05-04
US12251386B2 (en) 2025-03-18
AU2013245878A1 (en) 2014-10-30
PL3184523T3 (pl) 2019-12-31
KR102438340B1 (ko) 2022-08-30
KR102120883B1 (ko) 2020-06-09
IL296199B2 (en) 2024-12-01
US20210137936A1 (en) 2021-05-13
EP3628670B1 (en) 2022-10-12
RS55690B1 (sr) 2017-07-31
ES2745016T3 (es) 2020-02-27
AU2013245878B2 (en) 2017-10-12
HRP20191653T1 (hr) 2020-02-21
DK3184523T3 (da) 2019-08-19
EP2836491A1 (en) 2015-02-18
IL266165A (en) 2019-06-30
US20170143729A1 (en) 2017-05-25
KR20250005505A (ko) 2025-01-09
MX362339B (es) 2019-01-11
RU2014145544A (ru) 2016-06-10
MX2014012380A (es) 2015-07-23
AU2018200168A1 (en) 2018-02-01
AU2018200168B2 (en) 2019-08-29
ES2617379T3 (es) 2017-06-16
SI3184523T1 (sl) 2020-04-30
US11491163B2 (en) 2022-11-08
HUE045353T2 (hu) 2019-12-30
JP2018199740A (ja) 2018-12-20
PL3628670T3 (pl) 2023-02-20
DK2836491T3 (en) 2017-03-06

Similar Documents

Publication Publication Date Title
US12251386B2 (en) Salt form of a human histone methyltransferase EZH2 inhibitor
HK40087682A (en) Hbr salt form for ezh2 inhibition
HK40026825B (en) Salt form for ezh2 inhibition
HK40026825A (en) Salt form for ezh2 inhibition

Legal Events

Date Code Title Description
RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20151126

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20151130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160411

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160411

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A132

Effective date: 20161130

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20161130

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170227

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170427

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170531

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170612

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171012

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20171019

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20171107

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20171204

R150 Certificate of patent or registration of utility model

Ref document number: 6255382

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250